Abstract
Targeting metalloproteinases has been in the focus of drug design for a long time. However, meprin α and β emerged as potential drug targets just recently and are linked to several diseases with different pathological background. Nevertheless, the validation of meprins as suitable drug targets still requires highly potent and selective inhibitors as chemical probes to elucidate their role in pathophysiology. Albeit highly selective inhibitors of meprin β have already been reported, only inhibitors of meprin α with modest activity or selectivity are known. Starting from recently reported heteroaromatic scaffolds, the aim of this study was the optimisation of meprin α and/or meprin β inhibition while keeping the favourable off-target inhibition profile over other metalloproteases. We report potent pan-meprin inhibitors as well as highly active inhibitors of meprin α with superior selectivity over meprin β. The latter are suitable to serve as chemical probes and enable further target validation.
Acknowledgements
We gratefully acknowledge Antje Hamann and Christian Pfennig (IZI-MWT), Dr. Christoph Wiedemann, and Dr. Christian Ihling (Martin Luther University, Halle–Wittenberg) for their excellent technical support.
Disclosure statement
M. B. is an employee of PerioTrap Pharmaceuticals GmbH. C. J. is an employee of Vivoryon Therapeutics N.V., Halle (Saale), Germany. The remaining authors declare no competing interests.
Preprint
A previous version of this manuscript has been deposited as a preprint on ChemRxiv (DOI: 10.26434/chemrxiv-2022-jflzq).
Correction Statement
This article has been republished with minor changes. These changes do not impact the academic content of the article.